Table 4 Baseline clinico-radiological-pathological characteristics in 40 prostate cancer cases who performing both systematic template and MRI-US fusion guided prostate biopsy with identifiable extraprostatic extension through transrectal or transperineal approach
Variables | All | TR | TP | p value |
|---|---|---|---|---|
Patients, n (%) | 40 (100) | 20 (50.0) | 20 (50.0) | |
Median yrs age (IQR) | 71 (64–76) | 72 (66–78) | 73 (63–75) | 0.904 |
Median ng/ml PSA (IQR) | 11.9 (6.1–17.2) | 9.53 (5.8–13.9) | 14.5 (6.8–30.9) | 0.056 |
Median cc prostate vol (IQR) | 52 (38–66) | 52 (39–70) | 52 (34–65) | 0.620 |
Median ng/ml/cc PSA density (IQR) | 0.25 (0.14–0.44) | 0.17 (0.12–0.25) | 0.35 (0.24–0.71) | 0.005 |
Indication for biopsy, n (%) | 0.223 | |||
Elevated PSA, no prior biopsy | 31 (77.5) | 15 (75.0) | 16 (80.0) | |
PCa + active surveillance | 6 (15.0) | 2 (10.0) | 4 (20.0) | |
Elevated PSA + prior negative biopsy | 3 (7.5) | 3 (15.0) | 0 (0) | |
Median index diameter (cm) | 2.3 (1.5–3.5) | 2.3 (1.5–3.4) | 2.5 (1.5–4.1) | 0.445 |
No. targets on MRI, n (%) | 0.451 | |||
1 | 31 (77.5) | 17 (85.0) | 14 (70.0) | |
>1 | 9 (22.5) | 3 (15.0) | 6 (30.0) | |
PI-RADS score (index), n (%) | 1.000 | |||
3 | 2 (5.0) | 1 (5.0) | 1 (5) | |
4 | 8 (20.0) | 4 (20.0) | 4 (20.0) | |
5 | 30 (75.0) | 15 (75.0) | 11 (75.0) | |
Primary location (index) on MRI, n (%) | 0.407 | |||
Transitional zone | 1 (2.5) | 1 (5.0) | 0 (0) | |
Peripheral zone | 32 (80.0) | 17 (85.0) | 15 (75.0) | |
Multiple zones | 7 (17.5) | 2 (10.0) | 5 (25.0) | |
Secondary location (index) on MRI, n (%) | 0.458 | |||
Posterior | 25 (62.5) | 14 (70.0) | 11 (55.0) | |
Anterior | 3 (7.5) | 2 (10.0) | 1 (5.0) | |
Both | 12 (30.0) | 4 (20.0) | 8 (40.0) | |
Laterality (index), n (%) | 0.668 | |||
Right | 12 (30.0) | 5 (25.0) | 7 (35.0) | |
Left | 18 (45.0) | 9 (45.0) | 9 (45.0) | |
Both | 10 (25.0) | 6 (30.0) | 4 (20.0) | |
EPE suspected on MRI, n (%) | 1.000 | |||
Present | 18 (45.0) | 11 (55.0) | 11 (55.0) | |
Absent | 22 (55.0) | 9 (45.0) | 9 (45.0) | |
Total Gleason Grade Group, n (%) | 0.630 | |||
2 | 6 (15.0) | 2 (10.0) | 4 (20.0) | |
3 | 5 (12.5) | 3 (15.0) | 2 (10.0) | |
4 | 11 (27.5) | 7 (35.0) | 4 (20.0) | |
5 | 18 (45.0) | 8 (40.0) | 10 (50.0) | |
Gleason Grade Group in EPE, n (%) | 0.020 | |||
1 | 1 (2.5) | 1 (5.0) | 0 (0) | |
2 | 6 (15.0) | 1 (5.0) | 5 (25.0) | |
3 | 10 (25.0) | 8 (40.0) | 2 (10.0) | |
4 | 11 (27.5) | 7 (35.0) | 4 (20.0) | |
5 | 12 (30.0) | 3 (15.0) | 9 (45.0) | |
PNI (Combined), n (%) | 1.000 | |||
Present | 39 (97.5) | 19 (95.0) | 20 (100) | |
Absent | 1 (2.5) | 1 (5.0) | 0 (0) | |
PNI in EPE | 1.000 | |||
Present | 36 (90.0) | 18 (90.0) | 18 (90.0) | |
Absent | 4 (10.0) | 2 (10.0) | 2 (10.0) | |
Median PCa-positive cores (IQR) | ||||
SBx | 10 (5–13) | 8 (3–11) | 10 (8–15) | 0.023 |
TBx | 4 (3–5) | 4 (3–5) | 4 (3–5) | 0.904 |
Median PCa-positive core rate (IQR) | ||||
SBx | 0.73 (0.35–0.94) | 0.63 (0.29–0.98) | 0.73 (0.41–0.94) | 0.968 |
TBx | 1.00 (0.88-1.00) | 1.00 (0.81-1.00) | 1.00 (1.00–1.00) | 0.565 |
Median GPC (IQR) | ||||
SBx | 0.95 (0.80-1.00) | 0.95 (0.75-1.00) | 0.95 (0.80-1.00) | 0.947 |
TBx | 0.95 (0.85-1.00) | 0.95 (0.74-1.00) | 0.95 (0.86-1.00) | 0.904 |
Median GPC with EPE (IQR) | ||||
SBx | 0.90 (0.64–0.98) | 0.90 (0.48–0.95) | 0.95 (0.80-1.00) | 0.310 |
TBx | 0.95 (0.85–0.99) | 0.95 (0.70-1.00) | 0.95 (0.85–0.95) | 0.941 |